Latest news with #TCR-based
Business Wire
25-04-2025
- Business
- Business Wire
CDR-Life Presents Promising Preclinical Data for Novel T Cell Engager Programs at AACR Annual Meeting 2025
ZURICH--(BUSINESS WIRE)-- CDR-Life today announced the presentation of data for its novel T cell engager (TCE) programs at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. The presentations showcase the company's proprietary M-gager® platform-derived TCE candidates, with a focus on CDR404, currently in Phase 1 clinical trials for MAGE-A4-positive solid tumors. 'The data presented at AACR highlight the potential advantages of our antibody-based approach to T cell engagement against highly tumor-specific targets,' said Christian Leisner, PhD, Chief Executive Officer of CDR-Life. Share 'The data presented at AACR highlight the potential advantages of our antibody-based approach to T cell engagement against highly tumor-specific targets,' said Christian Leisner, PhD, Chief Executive Officer of CDR-Life. 'CDR404 demonstrated superior potency and durability in preclinical models, which align with the encouraging early signals we're seeing in our ongoing Phase 1 trial.' Key Findings for CDR404 in MAGE-A4-Positive Tumors (Abstract #3494) The poster, 'Durable and potent in vitro T cell activity with repeated exposure to CDR404, a potential best-in-class T cell engager targeting MAGE-A4' demonstrated several advantages of CDR404 compared to a TCR-based TCE: Superior Potency and Durability: CDR404 showed more potent killing of MAGE-A4-positive cancer cell lines across multiple indications, even at low effector-to-target cell ratios which mimic a 'cold' tumor environment, compared to a TCR-based competitor Enhanced T Cell Fitness: After multiple rounds of serial killing, T cells exposed to CDR404 maintained significantly better fitness, with lower levels of crucial T cell exhaustion markers compared to the TCR-based approach Favorable Cytokine Profile: CDR404 demonstrated a more favorable cytokine release profile, potentially offering safety advantages in the clinical setting Effective Across Multiple Cancer Types: CDR404 showed strong activity against MAGE-A4-positive tumor cells from different cancer types, including lung adenocarcinoma and squamous cell carcinoma, and melanomas The data presented in the poster align well with early emerging data from the ongoing Phase 1 trial of CDR404 (NCT06402201). CDR404 has shown clear signals of immunological activity and preliminary evidence of anti-tumor activity, including at the pharmacokinetic model-derived starting dose. Use of this innovative model created an elevator to a higher starting dose, potentially shortening overall trial duration by enabling a starting dose closer to the efficacious dosing range while maintaining patient safety. Dose escalation is ongoing and patient data from the early stages of the Phase 1 trial will be reported later this year. Second T Cell Engager for KK-LC-1-Positive Tumors (Abstract #3493) In the poster, 'A novel T cell engager antibody for the treatment of HLA-A01/KK-LC-1-positive tumors,' CDR-Life presented data on CDR505, a novel antibody-based TCE targeting the Kita-Kyushu lung cancer antigen-1 (KK-LC-1) presented on HLA-A01:01. Key findings for CDR505 included: Potent and Selective: CDR505 demonstrated potent and selective killing of KK-LC-1-positive cancer cells. Preferential T Cell Activation: The molecule showed preferential activation of CD8+ T cells, confirming the intended mechanism of action. High Target Specificity: CDR505 exhibited high specificity for the KK-LC-1 peptide/HLA-A*01:01 complex, demonstrating low risk for off-target binding. Desirable Pharmaceutical Properties: The molecule demonstrated excellent manufacturability, solubility and stability characteristics, supporting its feasibility for subcutaneous formulation. Broad Patient Potential Both TCE candidates have the potential to address significant patient populations: CDR404 targets MAGE-A4-positive tumors in HLA-A02:01-positive patients. MAGE-A4 is expressed in up to 63% of ovarian cancers, 62% of head and neck cancers and 52% of squamous lung cancers. CDR505 is the only TCE in development targeting KK-LC-1-positive tumors in HLA-A*01:01-positive patients. KK-LC-1 is expressed in 75% of colorectal and gastric carcinoma cancers and 60% of pancreatic ductal adenocarcinoma cancers. 'With CDR505, we're breaking new ground in targeting previously inaccessible cancer antigens through our innovative M-gager® platform,' added Dr. Leisner. 'This first-in-class molecule demonstrates how we're tackling difficult targets with precision, particularly in tumor types where traditional approaches have shown limited success. The widespread expression of KK-LC-1 across gastrointestinal cancers positions CDR505 to potentially address some of medicine's most challenging malignancies with a novel immunotherapeutic approach.' About CDR-Life CDR-Life develops highly targeted T cell engagers (TCEs) for the treatment of solid cancers and autoimmune diseases. Our M-gager® platform delivers TCEs against challenging intracellular and surface antigens through unparalleled target-specificity. With our first oncology program now in clinical trials, we are advancing a pipeline of potent and selective TCE therapeutics. Our partnership with Boehringer Ingelheim on a molecule derived from our M-gager® platform, progressing to Phase 2 trials, demonstrates the potential of our antibody-derived molecules. Backed by leading cross-Atlantic investors, our team is committed to bringing life-changing, disease-modifying medicines to patients globally. Learn more at
Associated Press
18-04-2025
- Health
- Associated Press
TCR Therapy Market Research Report 2025-2035: NY-ESO-1 Target Antigen is Likely to Dominate, Multiple Myeloma Segment Occupies the Largest Share
DUBLIN--(BUSINESS WIRE)--Apr 18, 2025-- The 'TCR Therapy Market Industry Trends and Global Forecasts to 2035, by Target Indication, Target Antigen, Key Players and Key Geographies' report has been added to offering. The global TCR therapy market is estimated to grow from USD 0.03 billion in the current year to USD 4.13 billion by 2035, at a CAGR of 51% during the forecast period, till 2035. Cancer continues to be one of the key areas of research and drug development within the pharmaceutical industry. In fact, in the past few years, the USFDA has approved more than 70 drugs for the treatment of different types of cancer. Given the challenges associated with conventional therapies, such as non-specificity and several side effects including gastrointestinal and cardiovascular toxicities, drug developers are actively investigating targeted anti-cancer therapies. Of these, modified T-cell receptor (TCR) based therapies have emerged as a promising option. TCR therapy utilizes genetically modified lymphocytes to target specific tumor markers. TCR therapies have been demonstrated to selectively target and eliminate tumor cells from the body of a host with minimal treatment-related side effects. Notably, over 110 clinical trials related to TCR therapies have been registered in the past ten years, indicating substantial research activity. Driven by a promising development pipeline and encouraging clinical trial results, the TCR-based therapy market is likely to witness significant growth in the mid to long-term. Global TCR Therapy Market: Key Segments Currently, Multiple Myeloma Segment Occupies the Largest Share of the Global TCR Therapy Market Based on target indication, the market is segmented into nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and Merkel cell cancer. At present, the multiple myeloma segment holds the maximum share of the global TCR therapy market. It is worth highlighting that the TCR therapy market for nasopharyngeal carcinoma is likely to drive the market in the near future. NY-ESO-1 Target Antigen is Likely to Dominate the Global TCR Therapy Market During the Forecast Period Based on the target antigen, the market is segmented into NY-ESO-1, EBV and gp100. Currently, NY-ESO-1 antigen holds the maximum share within the TCR therapy market. This trend is unlikely to change in the near future. North America Accounts for the Largest Share of the Market Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, and the Rest of the world. Majority share is expected to be captured by drug developers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR. Global TCR Therapy Market: Key Insights The report delves into the current state of the global TCR therapy market and identifies potential growth opportunities within the industry. Some key findings from the report include: Primary Research Overview The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders: Some Key Players in the Global TCR Therapy Market include: Product Wise Sales Forecast Key Topics Covered: 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Pillars of Cancer Therapy 3.3. Overview of Immunotherapies 3.4. Fundamentals of Cancer Immunotherapy 3.5. Classification of Cancer Immunotherapies 3.6. T Cell Immunotherapies 3.7. T-Cell Receptor (TCR)-based Cell Therapy 3.8. Concluding Remarks 4. TCR THERAPIES: MARKET LANDSCAPE 4.1. Chapter Overview 4.2. TCR Therapies: Overall Market Landscape 4.3. TCR Therapies: Overall Developer Landscape 5. POPULAR TARGET ANTIGEN ANALYSIS 5.1. Chapter Overview 5.2. Competitive Analysis: Popular Target Antigens of TCR Therapies 6. CLINICAL TRIAL ANALYSIS 6.1. Chapter Overview 6.2. Scope and Methodology 6.3. TCR Therapies: Clinical Trial Analysis 7. KEY OPINION LEADERS 7.1. Chapter Overview 7.2. Assumptions and Key Parameters 7.3. Methodology 7.4. TCR Therapies: Key Opinion Leaders 8. T CELL RECEPTOR THERAPY PROFILES 8.1. Chapter Overview 8.2. Kimmtrak / IMCgp100 / Tebentafusp (Immunocore) 8.3. GSK3377794 / NY-ESO-1C259 T-cells / Letetresgene Autoleucel (GlaxoSmithKline) 8.4. ADP-A2M4 / Afamitresgene Autoleucel / Afami-cel (Adaptimmune Therapeutics) 8.5. JTCR016 (Juno Therapeutics) 8.6. TBI-1301 (Takara Bio) 8.7. MDG1011 (Medigene) 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. TCR Therapies: Partnerships and Collaborations 10 FUNDING AND INVESTMENT ANALYSIS 10.1. Chapter Overview 10.2. Types of Funding 10.3. TCR Therapies: Funding and Investment Analysis 11. PATENT ANALYSIS 11.1. Chapter Overview 11.2. Scope and Methodology 11.3. TCR Therapies: Patent Analysis 12. CASE STUDY: CELL THERAPY MANUFACTURIN G 12.1. Chapter Overview 12.2. Overview of Cell Therapy Manufacturing 12.3. Cell Therapy Manufacturing Models 12.4. Scalability of Cell Therapy Manufacturing Processes 12.5. Types of Cell Therapy Manufacturers 12.6. Key Challenges Related to Manufacturing of Cell Therapies 12.7. Important Factors for Cell Therapy Manufacturing 12.8. Automation of Cell Therapy Manufacturing Processes 12.9. Cell Therapy Manufacturing Supply Chain 12.10. Comparison of Player Having In-House Capabilities and Contract Manufacturers 12.11. Regulatory Landscape 12.12. Future Perspectives 13. COST PRICE ANALYSIS 13.1. Chapter Overview 13.2. Factors Contributing to the High Price of Cell / Gene Therapies 13.3. Pricing Models for T-Cell Immunotherapies 13.4. Reimbursement related Considerations for T-cell Immunotherapies 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 14.1. Chapter Overview 14.2. Scope and Limitations 14.3. Key Assumptions and Forecast Methodology 14.4. Global TCR Therapy Market, 2022-2035 15. PROMOTIONAL ANALYSIS 15.1. Chapter Overview 15.2. Channels Used for Promotional Campaigns 15.3. Kimmtrak: Promotional Analysis 16. COMPANY PROFILES 16.1. Chapter Overview 16.2. Adaptimmune Therapeutics 16.3. Alaunos Therapeutics 16.4. Company Profiles 16.5. Bristol Myers Squibb 16.6. Cellular Biomedicine Group 16.7. Gilead Sciences 16.8. Cellular Biomedicine Group 16.9. GlaxoSmithKline 16.10. Immatics 16.11. Immunocore 16.12. Lion TCR 16.13. Takara Bio 16.14. Zelluna immunotherapy 17. CONCLUDING REMARKS 18. EXECUTIVE INSIGHTS 18.1. Chapter Overview 18.2. Celyad: Interview Transcript: Vincent Brichard, Vice President, Immuno-Oncology 18.3. Kite Pharma: Interview Transcript: Adrian Bot, Vice President, Scientific Affairs 18.4. Lion TCR: Interview Transcript: Victor Lietao Li, Co-Founder and Chief Executive Officer 18.5. TxCell: Interview Transcript: Miguel Forte, Chief Operating Officer 19. APPENDIX 1: TABULATED DATA 20. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS Additional Benefits For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH ONCOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 04/18/2025 11:42 AM/DISC: 04/18/2025 11:41 AM
